Structure Therapeutics (NASDAQ:GPCR) Shares Down 6.7% – What’s Next?

Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) dropped 6.7% during trading on Tuesday . The stock traded as low as $34.92 and last traded at $34.9410. Approximately 1,337,176 shares changed hands during trading, an increase of 45% from the average daily volume of 923,250 shares. The stock had previously closed at $37.44.

Wall Street Analyst Weigh In

GPCR has been the subject of several research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Structure Therapeutics in a report on Wednesday, October 8th. Lifesci Capital raised shares of Structure Therapeutics to a “strong-buy” rating in a research report on Monday, September 8th. JMP Securities lowered their target price on Structure Therapeutics from $89.00 to $87.00 and set a “market outperform” rating for the company in a report on Thursday, August 7th. HC Wainwright cut their price target on Structure Therapeutics from $75.00 to $60.00 and set a “buy” rating on the stock in a report on Thursday, August 7th. Finally, Zacks Research cut Structure Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Friday, October 17th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and two have given a Sell rating to the stock. According to MarketBeat, Structure Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $68.67.

Structure Therapeutics Stock Performance

The firm’s 50-day simple moving average is $28.17 and its 200 day simple moving average is $23.40. The stock has a market capitalization of $2.01 billion, a P/E ratio of -28.44 and a beta of -1.64.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.01). As a group, research analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -0.82 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Structure Therapeutics

Several large investors have recently made changes to their positions in GPCR. PNC Financial Services Group Inc. increased its holdings in Structure Therapeutics by 9.4% during the third quarter. PNC Financial Services Group Inc. now owns 4,828 shares of the company’s stock worth $135,000 after buying an additional 413 shares during the last quarter. Assetmark Inc. lifted its stake in Structure Therapeutics by 39.9% in the second quarter. Assetmark Inc. now owns 2,877 shares of the company’s stock valued at $60,000 after acquiring an additional 820 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in shares of Structure Therapeutics by 530.0% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock valued at $30,000 after acquiring an additional 901 shares during the period. ANTIPODES PARTNERS Ltd increased its stake in shares of Structure Therapeutics by 39.1% during the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 4,078 shares of the company’s stock worth $114,000 after purchasing an additional 1,146 shares during the last quarter. Finally, State of Wyoming bought a new stake in shares of Structure Therapeutics in the 2nd quarter valued at about $28,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.